You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunotherapy, anti-CD38 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Evan Syndrome
  • Treatment
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023

Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)

Recruiting
  • Antiphospholipid Syndrome
  • Thrombocytopenia
  • Anti-CD38 antibody Injection
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • STI-6129
  • Beijing, Beijing, China
  • +3 more
Jan 9, 2023

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
Jan 17, 2023

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Multiple Myeloma Trial in France, United Kingdom (CID-103)

Recruiting
  • Multiple Myeloma
  • Nantes, France
  • +3 more
Apr 21, 2022

Multiple Myeloma Trial in Canton (STI-6129)

Recruiting
  • Multiple Myeloma
  • STI-6129
  • Canton, Ohio
    Gabrail Cancer Center
Jun 29, 2022

Membranous Nephropathy Trial in Bergamo, Ranica (MOR202)

Recruiting
  • Membranous Nephropathy
  • Bergamo, BG, Italy
  • +1 more
Mar 4, 2022

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Recruiting
  • Plasma Cell Myeloma
  • Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 27, 2022

Antibody-mediated Rejection Trial in Vienna, Berlin (Felzartamab, Placebo)

Recruiting
  • Antibody-mediated Rejection
  • Vienna, Austria
  • +1 more
Aug 23, 2022

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25

Not yet recruiting
  • The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
  • CD25 prophylaxis
  • (no location specified)
Jun 20, 2023

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Multiple Myeloma Trial (Elranatamab (PF-06863135))

Temporarily not available
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • (no location specified)
Jul 15, 2022

Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)

Active, not recruiting
  • Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 10, 2023

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Healthy Volunteer Trial in Herston (TNB-738)

Recruiting
  • Healthy Volunteer
  • Herston, Queensland, Australia
    Q-Pharm Pty Ltd
Aug 3, 2022

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022